6D8-24927-72544
3 vaccinations
1 coded response
34 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 212 / MD
- Registered
- 2021-01-14
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-14
Registered in v-safe
-
2021-01-14
Dose 1 — Pfizer-BioNTech
- 2021-01-14
- 2021-01-16
- 2021-01-18
- 2021-01-19
- 2021-01-21
- 2021-01-28
-
2021-02-04
Dose 2 — Pfizer-BioNTech
- 2021-02-04
- 2021-02-05
- 2021-02-06
- 2021-02-07
- 2021-02-08
- 2021-02-11
- 2021-02-18
- 2021-02-25
- 2021-03-04
- 2021-03-11
- 2021-03-18
- 2021-05-06
- 2021-08-05
-
2021-12-03
Dose 3 — Pfizer-BioNTech
- 2021-12-04
- 2021-12-05
- 2021-12-06
- 2021-12-07
- 2021-12-08
- 2021-12-09
- 2021-12-10
- 2021-12-17
- 2021-12-24
- 2021-12-31
- 2022-01-07
- 2022-01-14
- 2022-03-04
- 2022-06-04
-
2022-12-03
Survey response — 12 months, dose 3MedDRA: Headache, Myalgia, Rhinorrhoea, Sinusitis — Feeling: Good · Be unable to work or attend schoolFree text: Runny nose, headache, sinusitis, sore musclesMedDRA releases: 2024-11 · check-in free text available
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-14 | Pfizer-BioNTech | |
| 2 | 2021-02-04 | Pfizer-BioNTech | |
| 3 | 2021-12-03 | Pfizer-BioNTech | No |
Free text
Release 12 — 12 months, dose 3
Symptoms: Runny nose, headache, sinusitis, sore muscles
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Headache | · | · | ✓ |
| SD | Myalgia | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
| SD | Sinusitis | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release